Macrophage Programing in Acute Lung Injury

NCT ID: NCT03844893

Last Updated: 2019-08-22

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 56 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2019-10-31
• Study Completion Date: 2023-03-31

Brief Summary

The histologic hallmarks of lung inflammation and in the extreme, acute respiratory distress syndrome (ARDS), include intense accumulation of inflammatory cells in the airspaces and interstitium, injury to alveolar epithelial and endothelial cells, loss of epithelial-capillary integrity and accumulation of edema fluid in the interstitium and airspaces. Accordingly, for alveolar repair to occur inflammation must be halted, debris and inflammatory cells removed, injured tissue cells replaced, and capillary barrier function re-established. Macrophages are key players in all of these. Here the investigators hypothesize that resident alveolar macrophages and recruited macrophages serve completely different functions, acting independently (i.e. division of labor) yet cooperatively (synergism).

Conditions

Acute Respiratory Distress Syndrome

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Interventions

Mini bal

Mini-BAL is a minimally invasive technique frequently used in the investigator's local intensive care units (ICUs) to obtain alveolar fluid samples from mechanically ventilated patients. This is typically done for microbial analysis.

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

1. Written, informed consent (by surrogate if unconscious or if altered mental status)

2. Admission to a Medical Intensive care unit

3. Orally/nasally intubated, evaluable within 24 h of intubation or onset of ARDS

4. Expected to remain mechanically ventilated for at least 48 h after the first study procedure.

Exclusion Criteria

1. Treatment with immunosuppressants in the prior 3 months (antineoplastic agents, tumor necrosis factor alpha antagonists, cyclosporine, methotrexate, azathioprine, or mycophenolate. Treatment with glucocorticoids for septic shock is acceptable).

2. History of solid organ or bone marrow transplantation

3. History of chronic lung disease (e.g. COPD, pulmonary fibrosis, cystic fibrosis)

4. Human immunodeficiency virus positivity

5. Severe or massive hemoptysis

6. At significant risk for bleeding (INR > 3 or PTT > 3x normal)

7. Presence of an advanced directive to withhold life-sustaining treatment

8. Morbid state or expected to survive less than 14 days because of an advanced co-morbid medical condition;

9. Pregnancy

• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Jewish Health

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Central Contacts

Christine Griesmer, MPH

Role: CONTACT

griesmerc@njhealth.org

303-398-1325

Other Identifiers

HS-3076

Identifier Type: -

Identifier Source: org_study_id